White House press secretary Karoline Leavitt opened her press briefing by railing against the recent court rulings against ...

A new variant of COVID-19 is circulating in parts of the world and may be driving an increase in cases in the eastern ...

The US Supreme Court has decided not to hear an appeal from a Massachusetts middle school student who argued his First ...

Moderna said on Friday it has filed a marketing application for the review of its updated COVID-19 vaccine with the U.S. Food ...

Moderna, the biotech company behind one of the original mRNA COVID-19 vaccines, is undergoing an AI-powered workplace transformation. In partnership with OpenAI, Moderna has created thousands of ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut around $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news ...

Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. Moderna met analysts’ revenue expectations last ...

Moderna could face suspension from Britain’s pharmaceutical trade body following a string of breaches of the regulatory code. The Covid vaccine maker is due to be audited by the Prescription ...

Moderna has been hit by massive insider selling over the last couple of years. The stock has a 52-week high of over $170 while Moderna entered 2020 trading below $20, making insiders more likely ...

I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock.

Shares of Moderna fell Friday after taking on steep losses a day earlier on the news that it plans to cut research and development spending by $1.1 billion by 2027. JP Morgan analysts, meanwhile ...

Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to take a “more ...